Bladder in Biological Technology

$10,000 ISSAC Award for Innovation Presented to MIT PhD

... the system is designed to deliver drugs into the bladder for a specific period of time. The device is ... Michael Cima and Robert Langer. bladder diseases affect 50 million people in the U.S. alone, and delivering drugs to the bladder is tricky business. The current options include ...

SEP Signs REGURIN(R) Deal

... urgency as may occur in patients with overactive bladder (OAB). Urinary incontinence is an embarrassing ... the contractions of the detrusor muscle in the bladder and increases bladder capacity.[2] It is well tolerated with a low ...

China Medical Technologies Receives SFDA Approval for Its Bladder Cancer FISH Probe

... that the Company has received approval for its bladder Cancer FISH Probe (the "Probe") from the State ... for early detection and monitoring the course of bladder cancer. It is designed to detect and identify ... loss of the p16 locus are present in the human bladder cells. A number of hospitals in China have ...

International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCool's New Investigational UroCool System

... and thereby provide a faster return of bladder control (continence) and possibly erectile ... with delicate nerves that control erections and bladder control. Historically, radical prostatectomy has ... robotic radical prostatectomy. Temporary loss of bladder control occurs in most men. While most ...

Cardium's InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study

... and thereby provide a faster return of bladder control (continence) and possibly erectile ... with delicate nerves that control erections and bladder control. Historically, radical prostatectomy has ... robotic radical prostatectomy. Temporary loss of bladder control occurs in most men. While most ...

Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results

... currently approved for use in BCG-refractory bladder cancer patients who are not candidates for bladder removal. "Fiscal 2008 was also an active ... in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for hypogonadism, PRO 2000 for ...

Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries

... thereby provide a faster return of bladder control (continence) and possibly erectile ... with delicate nerves that control erections and bladder control. Historically, radical prostatectomy has ... cystectomy, a common procedure used to treat bladder cancer that has spread into the bladder wall. ...

deCODE genetics Announces Third Quarter 2008 Financial Results

... to their yearly mammogram. Target Discovery - bladder cancer. deCODE and colleagues in the Netherlands ... (SNPs) that confer increased risk of urinary bladder cancer. Approximately 20% of people of ... them at a 50% higher risk of developing bladder cancer than those without the variant. ...

Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast

... during the webcast was the opening of the bladder neck. "I like to open the bladder neck early," said Samadi, who applies a ... a big median lobe, I like to see exactly what the bladder neck looks like very early on so there won't be ...

Collegiate Inventors Competition(R) Recognizes Top Student Inventors

... Michael Cima) Drug Delivery Device for bladder Disorders - A device that can be inserted nonsurgically into the bladder via the urethra, releasing a controlled dosage of a drug into the bladder through osmosis. Harvey Liu, University of ...

Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloitte's 2008 Washington State Technology 'Fast 50' for 5th Time in Past 7 Years

... and brand growth for both BladderScan(R) bladder volume instruments and GlideScope(R) Video ... its BladderScan(R) brand, a line of noninvasive bladder volume measurement instruments used in Urology, ... such as enlarged prostate (BPH) and overactive bladder (OAB). BladderScan(R) is also clinically proven ...

Lorus initiates development program exploring novel route of administration for LOR-2040

... drug LOR-2040 for the treatment of superficial bladder cancer. The new development program will ... of LOR-2040 into the bladder as a treatment for superficial or non-invasive bladder cancer. Formal toxicology evaluation, which ...

Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment

... Designation qualifies Tengion and its Neo- bladder Augment for EMEA regulatory incentives, including ... justifications have been provided that the Neo- bladder Augment may be of significant clinical benefit ... with spina bifida who suffer from neurogenic bladder and warrant surgical intervention for their ...

Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data

... of locally recurrent, BCG-refractory non-invasive bladder cancer. The trial will enroll approximately 50 ... in situ, the most aggressive form of non-invasive bladder cancer, and are unresponsive to standard therapy ... in a Phase 3 clinical study for the treatment of bladder cancer, and VB6-845, in Phase 1. The Company ...

Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)

... in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would ... could lead to development of metastatic bladder cancer. About Indevus Indevus ... compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO ...

Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function

... the Tengion Neo-Bladder Augment(TM) to restore bladder function in a well- established preclinical model of a bladder augmentation cystoplasty. These data were among ... one in pediatric patients with neurogenic bladder due to spina bifida, and the other in adult ...

Bioniche Reports Fiscal 2007 Year-End Results

... for our second Phase III pivotal trial in bladder cancer occurred after the end of Fiscal 2007, but ... Cell Wall-DNA Complex (MCC) in the treatment of bladder cancer patients whose condition is ... of the Phase III pivotal trial with Urocidin in bladder cancer patients whose condition is refractory ...

Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer

... the Company's drug candidate for non-invasive bladder cancer. The trial design was reviewed under a ... pivotal Phase 3 trial for EOquin in non-invasive bladder cancer patients demonstrates the significant ... are more than 500 thousand people suffering from bladder cancer in the United States and more than 935 ...

Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy

... "VALSTAR offers an effective alternative for bladder cancer patients who have failed BCG therapy and ... in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would ... could lead to development of metastatic bladder cancer. About Indevus Indevus Pharmaceuticals, ...

NeoGenomics Reports Second Quarter 2009 Results

... customer in developing their own capability to perform a portion of their bladder cancer FISH testing in-house while simultaneously working with them to ... to which we provide services. As a result, revenue from this customer's bladder cancer FISH testing declined by $278,000 in Q2 09 compared with Q2 08, ...

Noridian Medicare Now Covers Renessa(R) Treatment for Incontinence in Women

... CPT 0193T, transurethral, radiofrequency micro-remodeling of the female bladder neck and proximal urethra for stress urinary incontinence. This includes ... The probe heats multiple small treatment sites in the submucosa of the bladder neck and upper urethra, denaturing the patient's own collagen in the ...

Minimally Invasive Surgery: Olympus Further Enhances Credentials by Entering Into Exclusive Sales and Distribution Partnership With Market and Technology Leader Advanced Surgical Concepts

... products is constantly expanding. In Europe alone, around 900,000 gall bladder operations are carried out each year. Over the next few years, a larger number of gall bladder operations will be performed via the umbilicus. Experts predict a ...

Halozyme Therapeutics Reports 2008 Third Quarter Financial Results

... enzyme. Results should be available in mid-2009. -- A clinical study in bladder cancer patients has been initiated that will test immediate post operative ... rHuPH20 with mitomycin C immediately following transurethral resection of bladder tumor (TURBT). Results of this small safety study will be used to support ...

Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation

... in which either a Neo-Bladder Augment or the subject's own native urinary bladder was surgically implanted following an 80% cystectomy and evaluated ... showed that the Tengion Neo-Bladder Augment regained and maintained native bladder histology by three months. The study also demonstrated that the ...

Indevus Announces Private Placement of $105 Million of Non-Recourse Notes

... are marketed in the U.S. by Allergan, Inc. for the treatment of overactive bladder (OAB). "This transaction reflects the successful execution of our plan ... The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of ...

Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today

... tumors, including prostate, breast, non-small cell lung, ovarian, and bladder cancers. It has potential applicability as a therapeutic in a broad ... tumors including prostate, non-small cell lung, breast, ovarian, and bladder cancers. The Company anticipates that the safety profile for OGX-427 ...

Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008

... of its clinical-stage drug LOR-2040 for the treatment of superficial bladder cancer. - Completed a corporate reorganization resulting in ... LOR-2040 in AML, GLP-toxicology studies with LOR-2040 for the treatment of bladder cancer, and the advancement of our small molecule program into ...

Sonus Pharmaceuticals and OncoGenex Technologies to Merge

... tumors, including prostate, breast, non-small cell lung, ovarian, and bladder cancers. It has potential applicability as a therapeutic in a broad ... tumors including prostate, non-small cell lung, breast, ovarian, and bladder cancers. The company anticipates that the single-agent aspect of this ...

Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007

... the benefits and availability of the Urgent PC system to treat overactive bladder (OAB) symptoms to their patients. Our efforts and focus on the existing ... non-surgical neurostimulation therapy for the treatment of overactive bladder (OAB) symptoms. We also offer Macroplastique(R) Implants, a bulking agent ...

Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status

... agent under investigation for the treatment of advanced or metastatic bladder cancer and other tumor types. Vinflunine was developed by Pierre Fabre ... authorities and plan to file for the registration of vinflunine for bladder cancer in the first quarter of 2008," said P. Hurteloup, General Manager ...

Halozyme Therapeutics Reports 2007 Third Quarter Financial Results

... Phase I/IIa clinical trial for the treatment of superficial bladder cancer. Chemophase is a novel recombinant investigational therapeutic ... widely used anticancer drug mitomycin in 27 patients with superficial bladder cancer. Interim data from this ongoing trial is expected during the ...

Indevus Announces Allergan as New Partner for SANCTURA Brand

... (FDA). SANCTURA XR is indicated for the once-daily treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary ... The most advanced compounds in development include, VALSTAR(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of ...

OncoGenex Reports Second Quarter 2009 Financial Results

... with solid tumors; - initiation of an investigator-sponsored phase 1 clinical trial evaluating OGX-427 treatment in patients with bladder cancer; and - working capital needs, capital expenditures and general corporate purposes. "We achieved important strategic ...

AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule

... (nocturia), difficulty starting a urine stream (hesitancy and straining), decreased strength of the urine stream (weak flow), feeling that the bladder is not completely empty, an urge to urinate again soon after urinating and pain during urination (dysuria). Currently available therapies may improve ...

AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia

... (nocturia), difficulty starting a urine stream (hesitancy and straining), decreased strength of the urine stream (weak flow), feeling that the bladder is not completely empty, an urge to urinate again soon after urinating and pain during urination (dysuria). Currently available therapies may improve ...

OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial

... is being evaluated in a Phase 1 clinical trial for the treatment of solid tumors including prostate, non-small cell lung, breast, ovarian, and bladder cancers. Like OGX-011, this product candidate has potential as a treatment in a broad number of cancers. About OncoGenex OncoGenex is a ...

OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427

... is being evaluated in a Phase 1 clinical trial for the treatment of solid tumors including prostate, non-small cell lung, breast, ovarian, and bladder cancers. Like OGX-011, this product candidate has potential as a treatment in a broad number of cancers. About OncoGenex OncoGenex is a ...

Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models

... was active as a single agent in vitro in a number of cell lines, including breast cancer, lung cancer, pancreatic cancer, prostate cancer, and bladder cancer, and in several mouse xenograft cancer models. AT-406 also showed synergistic or additive effects when used together with tyrosine kinase ...

Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc.

... The compound may have utility in several major indications, including non-small cell lung cancer, breast cancer, colorectal cancer, multiple myeloma, bladder cancer, and melanoma. The Company intends to file an Investigational New Drug (IND) application for ACTB1003 and to commence clinical testing during ...

NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results

... Hospital infections: In May 2008, NovaBay successfully completed a Phase I trial that showed NVC-422 was well tolerated in the bladder as a lavage solution for catheterized patients. In November 2008, the company commenced patient enrollment in a Phase II exploratory study of ...